
    
      The study will only include women who are receiving treatment with Certolizumab Pegol (CZP)
      for an approved indication in accordance with their treating physician, although this study
      is non-interventional regarding treatment with CZP, it is considered interventional due to
      the collection of breast milk from the lactating mothers.
    
  